TL;DR
This study leverages computational drug repurposing to identify existing FDA-approved drugs that could treat Parkinson's disease (PD). They found two promising candidates, Omaveloxolone and Cyproheptadine, which showed neuroprotective effects in both cell and animal models of PD, offering a faster path to potential new treatments.
What Problem Does This Paper Address?
Parkinson's disease (PD) is a progressive neurodegenerative disorder that significantly impacts quality of life. Current treatments primarily manage symptoms and don't halt disease progression. Developing new drugs is a lengthy and costly process. This paper addresses the urgent need for effective treatments that can slow or stop PD progression by exploring drug repurposing, a strategy that identifies new uses for already approved drugs, thereby reducing development time and risk.
Methods
The researchers employed a multi-step computational and experimental approach:
- Drug-Target Network Construction: They integrated data from multiple databases (e.g., DrugBank, ChEMBL) to build a network of known PD genes and their associated FDA-approved drugs.
- Drug Candidate Identification: Using a network-based inference tool (NetInfer), they screened 2,453 FDA-approved drugs to identify potential candidates whose targets overlapped with known PD targets. This narrowed down the list to 176 potential candidates.
- Literature Review & Selection: A literature search was conducted to filter these candidates, prioritizing those not previously reported for PD treatment and showing potential pharmacoprotective effects. This resulted in 28 candidates.
- In Vitro Validation: The neuroprotective effects of selected compounds were tested using the SH-SY5Y cell line, a common model for PD, induced by MPP+. Cell viability was assessed using CCK8 assays.
- In Vivo Validation: Promising candidates were further evaluated in an MPTP-induced mouse model of PD. This involved assessing neuroinflammation markers (IL-6), dopaminergic neuron survival (Tyrosine Hydroxylase - TH), and neurological deficits (open-field test).
- Mechanistic Exploration: Western blotting, ELISA, and molecular docking were used to investigate the underlying molecular mechanisms of the most promising drugs, focusing on key signaling pathways like MAPK/NFκB and Keap1-Nrf2/ARE.
Datasets
- Databases for PD Genes: ClinGen, ClinVar, DisGeNET, GeneCards, OMIM, Phenopedia.
- Databases for Drug-Target Interactions: BindingDB, ChEMBL, DrugBank, IUPHAR-BPS Guide to PHARMACOLOGY, PharmGKB, Therapeutic Target Database.
- Drug Repurposing Prediction Tool: NetInfer.
- Protein Data Bank (PDB): For molecular docking (PDB IDs: 6SFO, 6ROG).
- PubChem: For obtaining 3D structures of Omaveloxolone and Cyproheptadine.
No new benchmarks were introduced; the study utilized existing databases and computational tools.
Key Insights and Ideas
- Computational Repurposing as a Viable Strategy: The study strongly supports computational drug repurposing as an efficient and cost-effective method for identifying novel therapeutic candidates for complex diseases like PD.
- Omaveloxolone and Cyproheptadine as Dual-Action Candidates: Both drugs showed promise, but through distinct mechanisms. Omaveloxolone targets oxidative stress via the Keap1-Nrf2/ARE pathway, while Cyproheptadine tackles neuroinflammation via the MAPK/NFκB pathway. This suggests a potential for combination therapy.
- Targeting Key PD Pathways: The research highlights the importance of addressing both neuroinflammation (IL-6, MAPK/NFκB) and oxidative stress (Nrf2/ARE) in PD pathogenesis, as these are critical for dopaminergic neuron survival.
- FDA-Approved Drugs Offer a Head Start: The focus on FDA-approved drugs means these candidates already have established safety profiles, potentially accelerating their path to clinical trials and patient use.
Key Results
- The computational approach identified 176 potential drug candidates, narrowing down to 28 with reported neuroprotective effects and no prior PD association.
- In vitro: Omaveloxolone and Cyproheptadine demonstrated significant neuroprotection in MPP+-induced SH-SY5Y cells.
- In vivo (MPTP mouse model):
- Cyproheptadine: Inhibited IL-6 expression and prevented TH downregulation via the MAPK/NFκB pathway. It also improved neurological deficits.
- Omaveloxolone: Alleviated TH downregulation, potentially through the Keap1-Nrf2/ARE pathway, and improved neurological deficits.
- Both drugs were shown to preserve dopaminergic neurons and improve motor function in the PD mouse model.
Limitations and Future Work
- Database Completeness: The authors acknowledge that their compilation of PD databases and drug information, while extensive, may not be exhaustive.
- Drug Prediction Database Limitations: The drug prediction database used might have inherent limitations and may not have undergone comprehensive authoritative evaluation.
- Ephedrine Unavailability: Ephedrine, identified as a potential candidate, could not be evaluated due to unavailability.
- Validation of Nrf2 Pathway: While evidence suggests Omaveloxolone activates the Keap1-Nrf2/ARE pathway, further validation using Nrf2-specific inhibitors is needed to confirm its causal role in neuroprotection.
- MPTP Model Limitations: The MPTP model mimics acute dopaminergic neuron loss and neuroinflammation but does not fully replicate the a-synuclein aggregation characteristic of human PD. Future studies should incorporate a-syn-based models (e.g., PFF models, transgenic mice) for a more comprehensive evaluation.
- Sample Size and Translational Relevance: While statistically significant results were observed, larger sample sizes in future studies would further strengthen the findings and enhance their translational relevance.
The study suggests that Omaveloxolone and Cyproheptadine are promising candidates for further investigation and potential clinical trials for Parkinson's disease.
Summary updated